Therefore, our results suggest that BRG1 is an essential target whose inhibition may overcome the differentiation blockade in FP-RMS cells, providing therapeutic opportunities for this highly malignant childhood cancer. This evidence concerns the gene SMARCA4 and childhood malignant neoplasm.